ChromaVision system improves HercepTest results
This article was originally published in Clinica
ChromaVision Medical Systems' Automated Cellular Imaging System (ACIS) "improves the interpretive scoring ability of even an inexperienced pathologist to a level above that of an expert pathologist in manual immunohistochemical assessment of HER2 status", the San Juan Capistrano, California-based company says. The claim is based on the findings of a study that compared ACIS-assisted immunohistochemical evaluation of HER2 protein expression to manual immunohistochemical evaluation and evaluation by fluorescence in situ hybridisation (FISH).
You may also be interested in...
Will the second wave of coronavirus lockdown have the same impact on the European consumer health industry? Speaking exclusively to HBW Insight from Germany, Merz Consumer Care CEO Frank Baldauf thinks not. Recently investing in premium beard care brand Brooklyn Soap and launching its tetesept Formula range in the Netherlands, Merz's Baldauf suggest that there will be less panic buying this time round and the CHC supply chain will hold up under pressure.
After a strong first quarter, Japan’s Towa Pharmaceuticals saw stability in its domestic revenues but a drop in revenues from its overseas business in its financial second quarter. After launching a series of molecules in June 2020, the company has lined up 10 launches for December 2020 as well.
Pfizer has revealed launch plans for its Nyvepria pegfilgrastim biosimilar, shortly after receiving formal European Commission approval.